2 results
Approved WMORecruiting
Phase 1Primary Objective• To determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of NVL-520 in patients with advanced ROS1-positive solid tumorPhase 2Primary Objective• To evaluate the ORR of NVL-520 at the RP2D in patients with…
Approved WMORecruiting
The purpose of this study is to characterize the safety and tolerability of OAV101 IT in participants who have discontinued treatment with nusinersen (Spinraza®) or risdiplam (Evrysdi®). The data from this study will expand on the data generated…